Adrenocortical carticnoma (ACC) is a rare malignancy with an incidence of 0.7–2.0
cases/million habitants/year. The diagnosis of malignancy relies on careful investigations of …

Background Adrenocortical carcinoma is a rare, aggressive cancer for which few treatment
options are available. Linsitinib (OSI-906) is a potent, oral small molecule inhibitor of both …

Background The clinical course of advanced adrenocortical carcinoma (ACC) is
heterogeneous. Our study aimed primarily to refine and make headway in the prognostic …

Adrenocortical carcinoma (ACC) originates from the adrenal cortex and is typically defined
by positive immunostaining for steroidogenic factor 1 (SF1), melanA (Mart1) markers but …

Background Adrenocortical carcinoma (ACC) is a rare tumor in which prognostic factors are
still not well established. Programmed Death Ligand-1 (PD-L1) expression in ACC and its …

Purpose Adrenocortical carcinoma (ACC) is a rare malignancy known for high rates of local
recurrence, though the benefit of postoperative radiation therapy (RT) has not been …

Background Adrenocortical cancer (ACC) is a rare disease with a dismal prognosis. The
majority of patients are diagnosed with advanced disease and raise difficult management …

Objective Thresholds of 2–20 hounsfield units (HU) in unenhanced computed tomography
(CT) are suggested to discriminate benign adrenal tumors (BATs) from malignant adrenal …

Background Adrenocortical carcinoma is a rare cancer, with an incidence in the literature of
0.5 to 2 cases per million population per year. Adult adrenocortical carcinoma has a poor …

Introduction Metastatic adrenocortical carcinoma (ACC) is rapidly fatal, with few options for
treatment. Patients with metachronous recurrence may benefit from surgical resection. The …